|
1
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H and Zhang S:
Epidemiology of lung cancer in China. Thorac Cancer. 6:209–215.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Henschke CI, McCauley DI, Yankelevitz DF,
Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW,
Koizumi J, Altorki NK, et al: Early Lung Cancer Action Project:
overall design and findings from baseline screening. Lancet.
354:99–105. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dimitroulis J and Stathopoulos GP:
Evolution of non-small cell lung cancer chemotherapy (Review).
Oncol Rep. 13:923–930. 2005.PubMed/NCBI
|
|
5
|
Donati V, Fontanini G, Dell'Omodarme M,
Prati MC, Nuti S, Lucchi M, Mussi A, Fabbri M, Basolo F, Croce CM,
et al: WWOX expression in different histologic types and subtypes
of non-small cell lung cancer. Clin Cancer Res. 13:884–891. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simon G, Sharma A, Li X, Hazelton T, Walsh
F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, et
al: Feasibility and efficacy of molecular analysis-directed
individualized therapy in advanced non-small-cell lung cancer. J
Clin Oncol. 25:2741–2746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma PC: Personalized targeted therapy in
advanced non-small cell lung cancer. Cleve Clin J Med.
79:(Electronic Suppl 1). eS56–eS60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu Z and Chai Y: Complete remission of
liver metastasis in a lung cancer patient with epidermal growth
factor mutation achieved with Icotinib. Thorac Cancer. 7:681–683.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe S, Tanaka J, Ota T, Kondo R,
Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, et
al: Clinical responses to EGFR-tyrosine kinase inhibitor
retreatment in non-small cell lung cancer patients who benefited
from prior effective gefitinib therapy: a retrospective analysis.
BMC Cancer. 11:12011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ,
Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et
al: Effect of crizotinib on overall survival in patients with
advanced non-small-cell lung cancer harbouring ALK gene
rearrangement: a retrospective analysis. Lancet Oncol.
12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukuoka M, Wu Y, Thongprasert S, Yang C,
Chu D, Saijo N, Watkins C, Duffield E, Armour A and Mok T:
Biomarker analyses from a phase III, randomized, open-label,
first-line study of gefitinib (G) versus carboplatin/paclitaxel
(C/P) in clinically selected patients (pts) with advanced non-small
cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol (ASCO Annual
Meeting). 27:Abst 8006. 2009.
|
|
13
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): an
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gainor JF, Sherman CA, Willoughby K, Logan
J, Kennedy E, Brastianos PK, Chi AS and Shaw AT: Alectinib salvages
CNS relapses in ALK-positive lung cancer patients previously
treated with crizotinib and ceritinib. J Thorac Oncol. 10:232–236.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakajima T, Yasufuku K, Suzuki M,
Hiroshima K, Kubo R, Mohammed S, Miyagi Y, Matsukuma S, Sekine Y
and Fujisawa T: Assessment of epidermal growth factor receptor
mutation by endobronchial ultrasound-guided transbronchial needle
aspiration. Chest. 132:597–602. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakairi Y, Nakajima T, Yasufuku K, Ikebe
D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, et
al: EML4-ALK fusion gene assessment using metastatic lymph node
samples obtained by endobronchial ultrasound-guided transbronchial
needle aspiration. Clin Cancer Res. 16:4938–4945. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan H, Lu J, Lu T, Gao J, Zhang J, Xu Y,
Wang M, Wu H, Liang Z and Liu T: Comparison of EGFR mutation status
between plasma and tumor tissue in non-small cell lung cancer using
the Scorpion ARMS method and the possible prognostic significance
of plasma EGFR mutation status. Int J Clin Exp Pathol.
8:13136–13145. 2015.PubMed/NCBI
|
|
18
|
Togashi Y, Soda M, Sakata S, Sugawara E,
Hatano S, Asaka R, Nakajima T, Mano H and Takeuchi K: KLC1-ALK: A
novel fusion in lung cancer identified using a formalin-fixed
paraffin-embedded tissue only. PLoS One. 7:e313232012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yi ES, Boland JM, Maleszewski JJ, Roden
AC, Oliveira AM, Aubry MC, Erickson-Johnson MR, Caron BL, Li Y,
Tang H, et al: Correlation of IHC and FISH for ALK gene
rearrangement in non-small cell lung carcinoma: IHC score algorithm
for FISH. J Thorac Oncol. 6:459–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu
X and Lu N: Diagnostic value of a novel fully automated
immunochemistry assay for detection of ALK rearrangement in primary
lung adenocarcinoma. Ann Oncol. 24:2589–2593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee JK, Kim TM, Koh Y, Lee SH, Kim DW,
Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, et al: Differential
sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR
mutation and ALK translocation. Lung Cancer. 77:460–463. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H, Boiselle PM, Shepard JO,
Trotman-Dickenson B and McLoud TC: Diagnostic accuracy and safety
of CT-guided percutaneous needle aspiration biopsy of the lung:
comparison of small and large pulmonary nodules. AJR Am J
Roentgenol. 167:105–109. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soria JC, Massard C and Le Chevalier T:
Should progression-free survival be the primary measure of efficacy
for advanced NSCLC therapy? Ann Oncol. 21:2324–2332. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakahara Y, Mochiduki Y, Miyamoto Y,
Nakahara Y and Katsura Y: Prognostic significance of the
lymphocyte-to-neutrophil ratio in percutaneous fine-needle
aspiration biopsy specimens of advanced nonsmall cell lung
carcinoma. Cancer. 104:1271–1280. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inamura K, Takeuchi K, Togashi Y, Hatano
S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, et
al: EML4-ALK lung cancers are characterized by rare other
mutations, a TTF-1 cell lineage, an acinar histology, and young
onset. Mod Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
